Chemed (NYSE:CHE) Raised to “Buy” at Wall Street Zen

Chemed (NYSE:CHE) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Sunday.

A number of other brokerages have also recently commented on CHE. Zacks Research raised shares of Chemed from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Oppenheimer lowered their price objective on shares of Chemed from $580.00 to $500.00 and set an “outperform” rating on the stock in a research note on Friday, February 27th. Royal Bank Of Canada increased their price objective on shares of Chemed from $422.00 to $436.00 and gave the company a “sector perform” rating in a research note on Monday, April 27th. Finally, Weiss Ratings raised shares of Chemed from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, April 29th. Two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Chemed presently has a consensus rating of “Hold” and an average price target of $501.50.

Chemed Stock Performance

Shares of CHE opened at $426.39 on Friday. The company has a 50-day simple moving average of $404.28 and a 200-day simple moving average of $425.06. The company has a quick ratio of 0.83, a current ratio of 0.85 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $5.66 billion, a PE ratio of 23.24, a P/E/G ratio of 1.60 and a beta of 0.54. Chemed has a 52-week low of $365.20 and a 52-week high of $578.57.

Chemed (NYSE:CHE) last announced its quarterly earnings results on Thursday, April 23rd. The company reported $5.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.30 by $0.35. The business had revenue of $657.51 million during the quarter, compared to the consensus estimate of $659.22 million. Chemed had a net margin of 10.23% and a return on equity of 27.18%. The business’s revenue was up 1.6% compared to the same quarter last year. During the same quarter last year, the firm posted $5.63 EPS. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. Equities research analysts predict that Chemed will post 22.3 earnings per share for the current fiscal year.

Insider Activity

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $421.13, for a total transaction of $842,260.00. Following the sale, the chief executive officer directly owned 90,219 shares of the company’s stock, valued at $37,993,927.47. This trade represents a 2.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 3.33% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Chemed

Several hedge funds have recently modified their holdings of the company. Maripau Wealth Management LLC boosted its stake in shares of Chemed by 5.4% during the 1st quarter. Maripau Wealth Management LLC now owns 970 shares of the company’s stock worth $366,000 after purchasing an additional 50 shares during the last quarter. Segall Bryant & Hamill LLC acquired a new stake in shares of Chemed during the 1st quarter worth about $2,293,000. Cim LLC boosted its stake in shares of Chemed by 1.6% during the 1st quarter. Cim LLC now owns 2,325 shares of the company’s stock worth $878,000 after purchasing an additional 37 shares during the last quarter. Amundi boosted its stake in shares of Chemed by 6,982.7% during the 1st quarter. Amundi now owns 35,555 shares of the company’s stock worth $13,431,000 after purchasing an additional 35,053 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its stake in shares of Chemed by 9.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 406 shares of the company’s stock worth $153,000 after purchasing an additional 35 shares during the last quarter. 95.85% of the stock is owned by institutional investors and hedge funds.

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.